83 completed, 52 unknown, 26 recruiting, 13 terminated. 62 Phase 3, 48 Phase 2, 41 Phase 4, 31 Not applicable, 4 Phase 1.
Follow Triptorelin Pamoate: new trials by email Literature Review of Triptorelin Pamoate trials Research Report on Triptorelin Pamoate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy Iparomlimab and Tuvonralimab (QL1706), Aromatase Inhibitor (AI), CDK4/6 inhibitor - Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 40 | 2026-10-01 | 2026-08-26 |
| Dual Trigger VS HCG Trigger for Final Oocyte Maturation in Normal Responders Dual trigger (human chorionic gonadotropin plus GnRH-agonist), hCG trigger - ICSI, IVF | Not applicable | Recruiting | Al-Azhar University | 100 | 2026-09-01 | 2026-10-06 |
| Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy - Prostate Cancer, mHSPC | Phase 3 | Recruiting | University College, London | 1500 | 2026-08-28 | 2026-10-16 |
| Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT Leuprolide, Degarelix, Relugolix - Prostate Cancer, Localized Prostate Carcinoma | Phase 2 | Recruiting | Baptist Health South Florida | 50 | 2026-07-29 | 2026-08-06 |
| Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 60 | 2026-03-09 | 2026-03-11 |
| COMPASS - COpenhagen MenoPAuSe Study Triptorelin 11.25 mg, Sodium Chloride 0.9%, Estradiol (E2) - Menopausal Osteoporosis, Bone Markers | Phase 2 | Recruiting | Martin Blomberg Jensen | 192 | 2025-10-02 | 2026-03-02 |
| The COSMYC Trial (COmbined Suppression of MYC) ZEN-3694, Testosterone cypionate, Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2025-08-19 | 2026-06-18 |
| Ultra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis Triptorelin (GnRH agonists), Hormone Replacement Therapy (HRT) - Deep Infiltrating Endometriosis (DIE), Infertility | Phase 4 | Recruiting | Li-jun Ding | 120 | 2025-08-01 | 2026-07-10 |
| Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer Gonadotropin Releasing Hormone Agonists and Antagonists, Bicalutamide, Biopsy Procedure - High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2025-04-16 | 2025-09-23 | |
| Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer Best Practice, Biospecimen Collection, Electronic Health Record Review - Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm | Phase 3 | Recruiting | Children's Oncology Group | 60 | 2025-02-27 | 2026-08-31 |
| Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer Luteinizing Hormone-Releasing Hormone (LHRH) analog, Androgen Receptor Signal Inhibitor (ARSI), Docetaxel - Metastatic Castration Sensitive Prostate Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 25 | 2025-01-10 | 2026-04-01 |
| Ovulation Trigger Strategies in Low Ovarian Reserve (TRIGGERBEST) Human chorionic gonadotropin (hCG), Follitropin delta, Triptorelin - Low Ovarian Reserve, Poor Ovarian Response | Phase 3 | Recruiting | Fundación para la Investigación del Hospital Clínico de Valencia | 126 | 2024-09-17 | 2026-09-11 |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer | Phase 2 | Recruiting | Mayo Clinic | 532 | 2024-06-03 | 2026-07-20 |
| Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained Infertility Resveratrol-based multivitamin supplement, Folic acid, IVF/ICSI - Unexplained Infertility | Not applicable | Unknown | Andros Day Surgery Clinic | 90 | 2024-06-01 | 2024-07-01 |
| Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment Recombinant Luteinizing Hormone (rLH), Recombinant Follicle-Stimulating Hormone (rFSH), Gonadotropin-Releasing Hormone Agonist (GnRH-a) - Infertility, Female, Luteinizing Hormone (LH) | Not applicable | Recruiting | Nanjing University | 590 | 2024-02-01 | 2025-08-19 |
| A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer Giredestrant, Triptorelin, Anastrozole - Breast Cancer | Phase 2 | Completed | ETOP IBCSG Partners Foundation | 231 | 2024-01-23 | 2026-02-24 |
| Effect GnRH Agonist Administration in Endometriosis Cyst Patients Triptorelin Embonate - Endometriosis | Phase 3 | Recruiting | Rumah Sakit Pusat Angkatan Darat Gatot Soebroto | 32 | 2024-01-02 | 2024-11-25 |
| Adenomyosis and Pregnancy: Levonorgestrel vs. GnRH for Blastocyst Transfer Triptorelin, levonorgestrel-releasing intrauterine system, frozen embryo transfer - Adenomyosis | Not applicable | Completed | Zagazig University | 184 | 2023-12-15 | 2024-09-03 |
| Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers Darolutamide, Darolutamide matched placebo, Radiotherapy - Prostate Cancer | Phase 2 / Phase 3 | Recruiting | Cancer Research Antwerp | 493 | 2023-12-13 | 2026-03-19 |
| Dose Escalation For INtraprostatic LEsions Prostate SBRT with Focal Boost, Triptorelin Injection - Prostatic Neoplasms | Phase 2 | Recruiting | Ottawa Hospital Research Institute | 54 | 2023-11-23 | 2024-01-05 |
Showing 20 of 189. Sign in to see all of them.
Prostatic Neoplasms (59) · Infertility (42) · Breast Neoplasms (15) · Infertility, Female (15) · Endometriosis (10) · Polycystic Ovary Syndrome (9) · Ovarian Hyperstimulation Syndrome (8) · Puberty, Precocious (6) · Neoplasm Metastasis (4) · Adenomyosis (3) · Lymphoma (3) · Neoplasms (3) · Helping Behavior (2) · Osteosarcoma (2) · Primary Ovarian Insufficiency (2)
Ipsen (17) · ETOP IBCSG Partners Foundation (6) · Mansoura University (5) · Damascus University (4) · Cairo University (3) · Debiopharm International SA (3) · Eugonia (3) · IVI Madrid (3) · Radiation Therapy Oncology Group (3) · Sheba Medical Center (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · UNICANCER (3) · Universitair Ziekenhuis Brussel (3) · Alexandria University (2) · American University of Beirut Medical Center (2)
United States (34) · Italy (21) · China (19) · Egypt (19) · Belgium (15) · Spain (15) · France (14) · Canada (12) · Israel (10) · United Kingdom (8) · Netherlands (6) · Germany (5) · Greece (5) · Switzerland (5) · Lithuania (4)
Abdul Hakim Nattouf, MD, PhD (4) · Marwan Alhalabi, MD, PhD (4) · Sally Kadoura, B Pharm, MD (4) · Mohamed S Abdelhafez, Dr (3) · Tryfon Lainas, PhD (3) · Hong Ye, bachelor (2) · Jingsong Zhang, MD, PhD (2) · Samuel Denmeade, MD (2) · Shi-Ling Chen, M.D., Ph.D. (2) · Waleed El-refaie, Dr (2) · Abdelhamid Benmachiche, M.D (1) · Abhishek Solanki, MD MS (1)
PMID 18192671, PMID 24881463, PMID 25592642, PMID 26092816, PMID 27044936, PMID 28911092, PMID 29863451, PMID 31618131, PMID 36521078, PMID 38421243, PMID 39783453, PMID 40986647, PMID 41637791, PMID 11473961, PMID 11937133, PMID 12202415, PMID 12909519, PMID 12970285, PMID 15070873, PMID 15890740, PMID 16556673, PMID 16926261, PMID 17222700, PMID 18086795, PMID 18249377, PMID 18258763, PMID 18309951, PMID 18320439, PMID 18403419, PMID 19380451, PMID 19403562, PMID 19516032, PMID 19797013, PMID 19888782, PMID 19909586, PMID 20008886, PMID 20159003, PMID 20334664, PMID 20797824, PMID 21247312, PMID 2161310, PMID 21736917, PMID 21771987, PMID 22412041, PMID 22429192, PMID 22587997, PMID 23129737, PMID 23249758, PMID 23394779, PMID 24095609
2005 (4), 2004 (2), 2016 (2), U10CA180820 (2), U10CA180868 (2), 2008 (1), 2009 (1), 2015 (1), 2017 (1), 2025 (1), I01CX002277 (1), P30CA076292 (1), P50CA272391 (1), R01CA286127 (1), R01CA300454 (1)